Description
Is Rutinib Cream 1.5% right for your situation?
Review these criteria with your dermatologist before enquiring- ✓Mild-to-moderate atopic dermatitis (12+) not adequately controlled by topical prescription therapies, non-immunocompromised
- ✓Nonsegmental vitiligo (12+) seeking targeted repigmentation therapy
- ✓Looking for a steroid-sparing topical option under dermatologist guidance
- ✓Seeking a WHO-GMP certified generic topical Ruxolitinib by Drug International
- ✗Treatment area exceeds 20% body surface area (10% for vitiligo)
- ✗Active, serious localized or systemic infection, or immunocompromised
- ✗On strong CYP3A4 inhibitors without dose review
- ✗Breastfeeding, or planning to within 4 weeks of last dose
Check Availability & Pricing
Prescription required · Named Patient Program · Worldwide shipping
🛡 WHO-GMP Certified · Prescription verified · Express dispatch
What is Rutinib Cream 1.5%?
Rutinib Cream 1.5% is a generic topical formulation of Ruxolitinib — a Janus kinase (JAK1/JAK2) inhibitor — manufactured by Drug International Ltd. under WHO-GMP certified conditions in Bangladesh. It contains the same active molecule as Opzelura® (Incyte), applied directly to affected skin for localised, targeted therapy.
It is approved for two distinct uses in patients 12 and older: short-term, non-continuous treatment of mild-to-moderate atopic dermatitis inadequately controlled by topical prescription therapies, and topical treatment of nonsegmental vitiligo.
| Generic name | Ruxolitinib (topical) |
| Reference brand | Opzelura® (Incyte) |
| Manufacturer | Drug International Ltd. |
| Standard | WHO-GMP Certified |
| Drug class | Topical JAK1/JAK2 Inhibitor |
| Dosage form | Cream — 1.5%, 15g/30g tube |
| Route | Topical · thin layer, twice daily |
| Prescription | Required — dermatologist |
How Ruxolitinib Cream Works
In atopic dermatitis and vitiligo, overactive JAK signalling drives the release of inflammatory cytokines that damage skin barrier function or destroy pigment-producing melanocytes.
What to Expect: First 30 Days
Atopic dermatitis and vitiligo respond on very different timelines — understanding this helps set realistic expectations.
- Week 1: Atopic dermatitis patients frequently notice rapid reduction in itching and early calming of redness.
- Weeks 2–3: Skin barrier continues to stabilise. For vitiligo, this is a foundational period — visible repigmentation takes much longer to appear.
- Week 4: Continued clearance of dermatitis lesions is typical. If atopic dermatitis shows no improvement by 8 weeks, your dermatologist should reassess. Vitiligo response may take up to 24 weeks to become meaningful.
Side Effects
Most side effects are mild and localised to the application site. Always tell your dermatologist how you are feeling, especially with any signs of infection.
Common · Usually Manageable
- Application site redness or stinging
- Acneiform eruptions
- Nasopharyngitis (common cold)
- Headache
- Application site itching
Serious · Report Immediately
- Serious localized or systemic infections
- Changes in blood counts (rare with topical use)
- Signs of hypersensitivity reaction
- Signs of a worsening skin infection (warmth, oozing, or worsening pain at the application site)
- Unexplained fever, chills, or extreme fatigue
How to Use Rutinib Cream 1.5%
Apply a thin layer twice daily to affected areas only. Do not exceed 60 g per week, and stay under 20% body surface area for atopic dermatitis or 10% for vitiligo. For external use only.
- 1Wash hands thoroughly before and after application.
- 2Apply a thin layer to affected skin only — more product does not improve results and increases systemic exposure risk.
- 3Avoid eyes, mouth, and open wounds — for external skin use only.
- 4Do not use occlusive dressings over treated areas unless specifically directed by your dermatologist.
Caregiver Guidance
- ♥Assist with application to hard-to-reach affected areas, ensuring only a thin layer is used.
- ♥Track weekly usage to keep within the strict 60 g/week limit.
- ♥Check application sites daily for worsening redness, swelling, or signs of infection.
If the Treatment Doesn’t Work
Frequently Asked Questions
How quickly does Rutinib Cream start working?
How does Rutinib Cream compare to Opzelura®?
Why is there a limit on how much I can apply?
How do I order Rutinib Cream through Meds For Cancer?
Meds For Cancer operates as a Named Patient Program (NPP) facilitator. Under this framework, WHO-GMP certified medicines are made available to individual patients with a confirmed medical need and a valid prescription, in countries where the branded product is unavailable or unaffordable.
This service does not constitute retail pharmacy dispensing. A prescription review is mandatory before any order is processed.
- Papp K, et al. Ruxolitinib cream for atopic dermatitis (TRuE-AD1/AD2). J Am Acad Dermatol 2021;85:863–872.
- Rosmarin D, et al. Ruxolitinib cream for vitiligo (TRuE-V1/V2). NEJM 2022;387:1445–1455.
- FDA Prescribing Information: Opzelura (ruxolitinib cream). Incyte, 2022.
Reviews
There are no reviews yet.